RenovoRx/$RNXT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About RenovoRx
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
Ticker
$RNXT
Sector
Primary listing
Employees
17
Headquarters
Website
RenovoRx Metrics
BasicAdvanced
$40m
-
-$0.33
1.00
-
Price and volume
Market cap
$40m
Beta
1
52-week high
$1.45
52-week low
$0.70
Average daily volume
294k
Financial strength
Current ratio
7.146
Quick ratio
6.584
Long term debt to equity
0.692
Total debt to equity
1.651
Profitability
EBITDA (TTM)
-12.367
Gross margin (TTM)
78.71%
Net profit margin (TTM)
-823.98%
Operating margin (TTM)
-830.69%
Revenue per employee (TTM)
$90,000
Management effectiveness
Return on assets (TTM)
-51.58%
Return on equity (TTM)
-100.47%
Valuation
Price to revenue (TTM)
22.129
Price to book
3.56
Price to tangible book (TTM)
3.56
Price to free cash flow (TTM)
-2.916
Free cash flow yield (TTM)
-34.30%
Free cash flow per share (TTM)
-0.305
Growth
Revenue change (TTM)
520.42%
Earnings per share change (TTM)
-13.86%
3-year earnings per share growth (CAGR)
-33.30%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs